Episode Details

Back to Episodes
POTUS, Pandemic is over

POTUS, Pandemic is over

Published 1 week, 3 days ago
Description
The pandemic is over (POTUS) https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines Emergency use authorizations August 31, 2022 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine, and the Pfizer-BioNTech COVID-19 Vaccine, to authorize bivalent formulations, for use as a single booster dose Original strain + BA.4 and BA.5 lineages For each bivalent COVID-19 vaccine, the FDA based its decision on the totality of available evidence, including extensive safety and effectiveness data for each of the monovalent mRNA COVID-19 vaccines, safety and immunogenicity data obtained from a clinical study of a bivalent COVID-19 vaccine that contained mRNA from omicron variant BA.1 lineage that is similar to each of the vaccines being authorized, Biden administration Has already placed an order for 170 million doses https://www.science.org/content/article/omicron-booster-shots-are-coming-lots-questions Data collected by the companies Human data, only available BA.1 booster BA.1 trails did not look for protection against severe disease, (People trials are very expensive) For the BA.4/BA.5 boosters, the companies have submitted animal data. (not released publicly) Pfizer presented preliminary findings in eight mice given BA.4/BA.5 vaccines as their third dose, (for EMA) Showed an increased antibody response to all Omicron variants tested: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Clinical trials for the BA.4/BA.5 vaccines will begin this month August 19, 2022 https://www.fda.gov/news-events/press-announcements/fda-roundup-august-19-2022 Today, the FDA authorized the emergency use of Novavax COVID-19 Vaccine, in individuals 12 through 17 years of age. This authorization follows a rigorous analysis and evaluation of the safety and effectiveness data conducted by the FDA. July 13, 2022 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, in individuals 18 years of age and older. June 17, 2022 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children Today, the U.S. Food and Drug Administration authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine, in children down to 6 months of age. December 22, 2021 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid

Learn more about your ad choices. Visit megaphone.fm/adchoices

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us